The launch of India’s first indigenous chimeric antigen receptor (CAR)-T cell therapy NexCAR19 (actalycabtagene autoleucel) last month at nearly 10% of the price of similar treatments available in the country was a truly significant moment.
Its impact on access was recognized not just by India’s president and the government, but also by Time magazine, which...